Alzinova AB ALZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 1.70
- Day Range
- SEK 1.01–1.22
- 52-Week Range
- SEK 1.01–3.92
- Bid/Ask
- SEK 1.13 / SEK 1.16
- Market Cap
- SEK 51.48 Mil
- Volume/Avg
- 1.2 Mil / 111,824
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody. The product is in clinical development as a therapeutic vaccine for the treatment of Alzheimer’s.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.alzinova.com
Valuation
|
Metric
|
ALZ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.64 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALZ
|
|---|---|
Quick Ratio | 4.91 |
Current Ratio | 4.91 |
Interest Coverage | −354.66 |
Quick Ratio
ALZ
Profitability
|
Metric
|
ALZ
|
|---|---|
Return on Assets (Normalized) | −14.05% |
Return on Equity (Normalized) | −14.78% |
Return on Invested Capital (Normalized) | −14.73% |
Return on Assets
ALZ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cpkynftp | Dmnk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sydztynq | Lrjxbyt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dngychzl | Cvdmdw | $97.8 Bil | |
MRNA
| Moderna Inc | Dcmrthvx | Tkmt | $38.8 Bil | |
ARGX
| argenx SE ADR | Xmsksnn | Zvdq | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vjfsxmcy | Kcpm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mjzhvxxz | Cbslxdf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zbwmnjg | Gwstrj | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ymryrxvqcp | Rlglrnz | $12.5 Bil | |
INCY
| Incyte Corp | Vfxmbsprq | Qpxtst | $11.5 Bil |